Skip to content

Doximity DOCS Cumulative Cost Basis

Cumulative Cost Basis at other companies

Veeva Systems logo
Veeva SystemsVEEV
Mirum Pharmaceuticals, Inc. logo
Mirum Pharmaceuticals, Inc.MIRM
Becton, Dickinson and Company logo
Becton, Dickinson and CompanyBDX
Genpact logo
GenpactG

Other financials

Income statement

See full
Revenue$145.4M+5.1%
Gross profit$126.0M+1.7%
Operating income$24.8M-49.0%
Net income$19.1M-69.4%
EPS (diluted)$0.10-67.7%

Balance sheet

See full
Cash & equivalents$219.2M+4.6%
Total debt$10.2M-17.8%
Total equity$950.8M-12.2%
Total assets$1.1B-11.1%

Cash flow

See full
Operating cash flow$109.5M+11.2%
CapEx-
Free cash flow$81.6M-17.1%

Valuation

See full
Market cap$3.75B-60.5%

Profitability

See full
Gross margin89.1%-1.1pp
Operating margin33.3%-6.6pp
Net margin30.4%-8.7pp
FCF margin50.6%+2.7pp

Returns & leverage

See full
Return on equity19.3%-3.2pp
Debt / equity0.0×
Current ratio6.1×-0.9×

Where this comes from

Reported directly by Doximity in its filing.

Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentGross.

The official record: Doximity’s 10-Q, filed February 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Doximity's cumulative cost basis.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Doximity's cumulative cost basis?
Doximity (DOCS) reported cumulative cost basis of $46.89M in Q4 2025.
How has Doximity's cumulative cost basis changed year-over-year?
Doximity's cumulative cost basis increased by 27.5% year-over-year, from $36.79M to $46.89M.
What is the long-term trend for Doximity's cumulative cost basis?
Over 4 years (2021 to 2025), Doximity's cumulative cost basis has grown at a 32.7% compound annual growth rate (CAGR), from $12.46M to $38.6M.